rs1024611 — CCL2 A-2518G

Promoter variant that increases CCL2 (MCP-1) transcription, amplifying monocyte recruitment to arterial walls and elevating atherosclerotic plaque risk

See your personal result for CCL2

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

CCL2 A-2518G — The Monocyte Recruitment Switch in Atherosclerosis

CCL2, also known as monocyte chemoattractant protein-1 (MCP-1), is the body's primary signal for drawing monocytes out of the bloodstream and into tissues. In healthy arteries, this recruitment is carefully controlled. In damaged or inflamed arteries, CCL2 expression surges, pulling monocytes into the arterial wall where they transform into foam cells — the lipid-laden macrophages that form the core of atherosclerotic plaques. The rs1024611 variant sits 2,518 base pairs upstream of the CCL2 coding sequence, directly in the gene's promoter region, where it acts as a molecular dial that turns up the volume on monocyte recruitment.

The Mechanism

The -2518 position in the CCL2 promoter overlaps a region that binds transcription factors controlling inflammatory gene expression. The G allele alters the binding affinity at this site, increasing basal and stimulated CCL2 transcription compared to the A allele. Functional studies in monocytes and endothelial cells show that G-allele constructs drive higher reporter gene activity than A-allele constructs under both resting conditions and inflammatory stimulation. The result is more circulating MCP-1 protein and a lower threshold for monocyte trafficking into inflamed tissues — including atherosclerosis-prone arterial segments at branch points and curvatures.

This mechanism is relevant beyond atherosclerosis. Elevated CCL2 drives monocyte infiltration in tuberculosis granulomas, HIV-associated vascular disease, and solid tumors. The -2518G allele consistently maps to conditions where monocyte overrecruitment is part of the pathology.

The Evidence

The most comprehensive cardiovascular data comes from a 2011 meta-analysis by Wang et al. — 24 studies, 9,844 CAD patients and 11,821 controls11 Wang et al. — 24 studies, 9,844 CAD patients and 11,821 controls
Wang Y et al. Genetic variants of the monocyte chemoattractant protein-1 gene and its receptor CCR2 and risk of coronary artery disease: a meta-analysis. Atherosclerosis. 2011;219(1):224-30. Under the recessive model, GG homozygotes showed OR 1.42 (95% CI 1.06-1.92) for CAD in Caucasians. However, when restricted to studies with 500 or more participants, the effect dropped to OR 1.08 (95% CI 0.85-1.37) — no longer significant. The authors flagged probable publication bias among smaller studies.

The earliest and most cited positive study is Szalai et al. 2001 — 638 participants (318 CAD surgery patients, 320 controls)22 Szalai et al. 2001 — 638 participants (318 CAD surgery patients, 320 controls)
Szalai C et al. Involvement of polymorphisms in the chemokine system in the susceptibility for coronary artery disease. Atherosclerosis. 2001;158(1):233-9. GG homozygotes were 2.2 times more likely to have severe CAD requiring bypass surgery (95% CI 1.25-3.92, p<0.005), and they also showed significantly higher lipoprotein(a) levels — a compounding cardiovascular risk factor.

Blood pressure is another downstream effect. Penz et al. 2010 — 66 asymptomatic ischemic heart disease patients33 Penz et al. 2010 — 66 asymptomatic ischemic heart disease patients
Penz P et al. MCP-1 -2518 A/G gene polymorphism is associated with blood pressure in ischemic heart disease asymptomatic subjects. Bratisl Lek Listy. 2010;111(8):420-5 found that G-allele carriers (AG + GG) had significantly higher systolic (p=0.037) and diastolic (p=0.021) blood pressure, and their calculated cardiovascular risk scores were nearly double those of AA carriers (3.17% vs 1.62%, p=0.004).

Not all studies agree. An Icelandic case-control study of 460 MI survivors and 1,842 controls found OR 0.87 (95% CI 0.71-1.08) — a null result in the opposite direction — illustrating the substantial heterogeneity across populations and study designs.

ClinVar classifies the G allele as a risk factor for coronary artery disease and as pathogenic for HIV-associated coronary artery disease, reflecting specific evidence that HIV amplifies the CCL2-driven vascular inflammation pathway beyond what occurs in HIV-negative individuals.

Practical Actions

For GG homozygotes, the evidence supports a focused cardiovascular surveillance strategy targeting the specific markers that this variant affects: monocyte-driven vascular inflammation and blood pressure. High-sensitivity CRP and lipoprotein(a) are particularly relevant — the Szalai 2001 study showed GG genotype paired with elevated Lp(a) created the highest CAD burden. Blood pressure monitoring is warranted because the Penz 2010 findings suggest the G allele's inflammatory effect manifests as measurable blood pressure elevation in established heart disease.

For AG heterozygotes, one G allele produces intermediate CCL2 expression — meaningfully above baseline but less than GG. Targeted monitoring of inflammatory cardiovascular markers is appropriate, especially in the presence of other risk factors.

Interactions

The CCL2 -2518G allele interacts with its receptor variant CCR2 rs1799864 (V64I). The CCR2 receptor is the primary target through which CCL2 recruits monocytes; variants in both the ligand (CCL2) and receptor (CCR2) can have additive effects on monocyte trafficking. The Wang 2011 meta-analysis analyzed both variants together, finding that CCR2 rs1799864 showed no independent CAD association in its own right, suggesting the ligand (CCL2) variant is the more functionally dominant of the two.

The rs1024611 G allele has also been studied in tuberculosis susceptibility and HIV-associated vascular disease — conditions where excess CCL2-mediated monocyte recruitment to infected or inflamed sites creates pathological tissue infiltration. These pleiotropic effects across diverse conditions reflect the centrality of CCL2 in monocyte biology.

Genotype Interpretations

What each possible genotype means for this variant.

AA Standard MCP-1 Expression Normal

Normal CCL2 promoter activity — baseline monocyte recruitment

The A/A genotype at the -2518 position maintains standard transcription factor binding at the CCL2 promoter. In the absence of inflammatory stimuli, CCL2 expression remains low. When injury or infection occurs, CCL2 rises appropriately to recruit monocytes and then returns to baseline. This controlled on/off pattern is associated with normal cardiovascular risk — no genetic amplification of the monocyte recruitment axis that underlies atherosclerotic plaque formation.

AG Elevated MCP-1 Expression Intermediate

One G allele — moderately elevated CCL2 expression and monocyte recruitment

The AG genotype produces more CCL2 transcript than AA, but less than GG. In the context of cardiovascular disease, this increased MCP-1 production raises the steady-state rate of monocyte recruitment to arterial walls — particularly at sites of endothelial stress. The Szalai 2001 study and Wang 2011 meta-analysis found that heterozygotes occupy an intermediate risk position, with the G allele exerting a codominant effect. The Penz 2010 study grouped AG with GG carriers, finding that both showed elevated blood pressure and cardiovascular risk scores compared to AA homozygotes.

GG High MCP-1 Expression High Risk

Two G alleles — highest CCL2 expression and strongest atherosclerotic risk signal

As a GG homozygote, both copies of your CCL2 promoter carry the G allele, which increases transcription factor binding and amplifies CCL2 gene expression above the levels seen in AA or AG carriers. The functional consequence is a lower threshold for monocyte recruitment into inflamed tissues, including atherosclerosis-prone arterial segments. The clinical significance, per ClinVar, is classified as pathogenic specifically for HIV-associated coronary artery disease — reflecting that HIV amplifies CCL2-mediated vascular inflammation into a more extreme phenotype in GG carriers.

The Wang 2011 meta-analysis found OR 1.42 (95% CI 1.06-1.92) for CAD in Caucasian GG carriers under the recessive model, though this effect was attenuated in large studies (OR 1.08, NS), suggesting the true effect is real but smaller than initial reports indicated. The Szalai 2001 finding of OR 2.2 for severe CAD requiring bypass surgery represents the strongest single study, though its sample size (638 participants) limits generalizability. The consistent finding across populations is a G-allele dose-response on CCL2 expression, which mechanistically connects to monocyte foam cell formation, plaque progression, and atherosclerotic cardiovascular events.